The core uses of the medicine relate to its function as a general anesthetic and an analgesic. The medication is commonly used in situations involving certain distressing symptoms by helping with the management of symptoms related to physical discomfort and awareness during medical interventions.

Therapeutic Relief and Clinical Scenarios

Калипсол is generally applied across patient groups, including both adults and children, and is used to manage general anesthesia, procedural sedation, and intense, acute pain stemming from trauma or surgical intervention. It is relevant in clinical settings that involve acute or disruptive symptom patterns, such as the emergency department or critical care. It offers symptomatic relief that helps patients who require management of symptoms linked to organ-specific functional stress (e.g., breathing and circulation) during a procedure. The medicine plays a role in managing symptoms that create noticeable physiological strain and contributes to easing the overall symptom load during periods of heightened symptoms.

“It supports patients during episodes of heightened discomfort and temporary physiological imbalance.”

Quick Fact: Supports management of Severe Pain and Procedural Awareness

Regulatory References

1. NIH StatPearls overview

The eligibility criteria for Калипсол (Ketamine hydrochloride) are strictly defined by regulatory agencies based on minimizing risk, especially related to the drug's effect on blood pressure and central nervous system dynamics.

Absolute Contraindications (Must Not Use)

The medicine is formally prohibited for patients with known hypersensitivity to the drug or any excipient. It is contraindicated for individuals in whom a substantial elevation of blood pressure would pose a serious hazard. This regulatory exclusion includes patients with severe, uncontrolled hypertension, severe coronary or myocardial disease, recent cerebrovascular accident (stroke), or conditions like eclampsia or pre-eclampsia.

Age-Group and Condition-Specific Restrictions

While Ketamine is indicated for use in both children and adults, caution is necessary for several populations. A key regulatory warning exists regarding the duration of use in children aged three years and younger. Use requires special caution in patients with pre-anesthetic elevated cerebrospinal fluid pressure. Furthermore, dose adjustments must be considered for patients with liver impairment, such as cirrhosis.

Pregnancy and Lactation Status

The drug is generally not recommended during pregnancy because safe use has not been established. An exception allows for its conditional use during specific delivery procedures. Use during the period of lactation is also generally not established or recommended.

Interactions with other medicines and products must be carefully managed due to the potential for compounded effects on the central nervous and cardiovascular systems. All patients must inform their healthcare provider of all current medications, including non-prescription products and supplements.

Documented Interactions

Interacting Product Category	Effect Summary	Clinical Constraint
CNS Depressants (Barbiturates, Narcotics/Opioids, Non-narcotic Analgesics)	Increased or prolonged central nervous system depression, which can lead to excessive sedation or respiratory compromise.	Close monitoring is required. Barbiturates must not be mixed in the same syringe or infusion solution with Калипсол due to chemical incompatibility and immediate precipitation.
Thyroid Hormones	Potential for additive effects on the cardiovascular system, possibly leading to hypertension and tachycardia (rapid heart rate).	Requires careful monitoring of cardiovascular function.
Antidiuretic Agents (e.g., Vasopressin)	Increased risk of hypertension and cardiac arrhythmias (irregular heartbeat) due to synergistic effects.	Requires close monitoring.
Non-depolarizing Muscle Relaxants	The muscle-relaxing effects of these agents may be potentiated or prolonged when administered concurrently.	Requires dosage adjustments and careful monitoring of recovery time.
Diazepam (and certain other Benzodiazepines)	May prolong the recovery period from anesthesia. Must be administered via a separate syringe and not mixed with the Калипсол solution.	Procedural restriction for administration.

The overall interaction profile requires vigilance, especially concerning the combination with other sedating medications and products that affect blood pressure and heart rate. These necessary restrictions and monitoring protocols are in place to ensure patient safety when Калипсол is administered.

How Калипсол works

The core action of Калипсол is its high-affinity, noncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, the primary excitatory ion channel in the central nervous system. By physically blocking this channel when activated, the molecule interrupts the glutamatergic transmission in the thalamocortical and limbic pathways, producing the resulting functional disconnection in the central nervous system . Secondary mechanistic domains involve partial agonism at μ-opioid receptors and the inhibition of norepinephrine reuptake. These secondary actions in the spinal cord and CNS contribute synergistically to the attenuation of nociceptive signal transmission. The resulting increase in synaptic norepinephrine indirectly stimulates the sympathetic nervous system, leading to the physiological consequence of increased heart rate and blood pressure via sympathetic nervous system activation. The medication is a racemic mixture of two mirror-image molecules, S(+)- and R(-)-Ketamine, which cooperate mechanistically; the S(+)-enantiomer exhibits greater affinity for the NMDA receptor, while both contribute to the full spectrum of molecular interactions, thereby shaping the drug's overall pharmacological action.

Калипсол is administered strictly via the parenteral route, utilizing either intravenous (IV) injection, IV continuous infusion, or intramuscular (IM) injection. Due to its status as a general anesthetic, administration must be performed by or under the direction of a physician with experience in general anesthetics in a specialized clinical setting. The dosage is always individualized and titrated to achieve the desired effect. The medication is officially indicated for use in both adults and children.

Administration and Dosing Principles

Dosage is determined based on body weight (mg/kg) and the chosen route of administration. The highest concentration available (100 mg/mL) requires dilution with approved solutions like 5% Dextrose or 0.9% Sodium Chloride injection before IV use. The initial IV induction dose must be delivered slowly over 60 to 120 seconds.

Administration Route	Initial Dose (Adults)	Maintenance Regimen
IV Injection	1 mg/kg to 4.5 mg/kg	Intermittent boluses of one-half to the full initial induction dose, repeated as needed.
IM Injection	6.5 mg/kg to 13 mg/kg	Not applicable (used for induction/short procedures).
IV Infusion	Not applicable	Continuous rate of 0.1 mg/min to 0.5 mg/min (titrated).

The duration of effect following a single dose is short, which necessitates the use of continuous IV infusion or intermittent dosing to maintain anesthesia for prolonged procedures. For procedures involving visceral stimulation, the medicine is officially used supplemented with an agent that addresses visceral discomfort.

Research Evidence / Overview of studies for Калипсол (Ketamine)

This section provides an overview of the research base for the medicine, focusing on what types of studies have been conducted, what outcomes they measured, and what remains unclear, consistent with regulatory and peer-reviewed scientific literature.

---

Evidence for Use in General Anesthesia and Procedural Sedation

The evidence landscape for the medicine's role as a general anesthetic and procedural sedative includes a substantial volume of research conducted over several decades. Studies in this area include Randomized Controlled Trials (RCTs) and numerous Observational Cohort Studies from operating rooms, emergency departments, and critical care settings. Researchers examined its use for inducing and maintaining a state suitable for diagnostic procedures, surgical interventions, and other distressing medical events.

Studies explored outcomes related to systemic or functional imbalance, such as patterns of heart rate and blood pressure, and monitored how the medication affects the airway and breathing reflexes. Findings describe patterns observed in these studies, including the monitoring of protective reflexes during the anesthetic state. Study outcomes also measured practical endpoints like the time required to achieve the desired state and the speed of recovery afterward. Evidence from these research scenarios contributes to the documentation base for its primary uses.

Evidence for Use in the Context of Acute, Intense Pain

Research has explored the use of this medicine in the context of acute, intense pain, such as pain related to trauma, fractures, or pain experienced immediately following major surgery. This evidence primarily consists of short-term RCTs where the medicine was evaluated in settings with varying symptom burdens against placebo or against other standard pain medications.

In these trials, studies monitored patient-reported outcomes describing perceived discomfort using standardized pain scales. Research also examined whether using this medicine was associated with a change in the total amount of concurrent pain medication required during the short-term recovery period. Findings describe patterns observed in these studies, including the measurement of changes in pain scores in the immediate post-treatment phase and, in some contexts, the monitoring of concurrent opioid use.

What Remains Uncertain and Areas of Active Research

Given the medicine's primary use as an anesthetic and use in acute pain, the majority of the regulatory research focuses on acute, immediate, or short-term symptom patterns measured during and immediately after a medical procedure. There is limited information for long-term outcomes regarding the repeated or sustained use of the standard anesthetic formulation of the medicine. Few studies have systematically monitored patients for outcomes related to systemic or functional imbalance over an extended period. The research is ongoing to fully characterize the optimal administration protocols for pain management, as comparative evidence is lacking in some contexts.

Research provides context, highlighting what is known about group patterns, but this evidence does not determine whether an individual will respond similarly.

Key Studies & References

1. Ketamine: NIH StatPearls
2. Ketamine for chronic non-cancer pain in adults: a systematic review and meta-analysis of randomised controlled trials

Common questions about Калипсол (FAQ)

Q: Can Kalipsol cause addiction or dependence?

Official regulatory bodies classify the active substance in Kalipsol as a Schedule III controlled substance. This classification is assigned due to the substance's recognized potential for misuse or abuse, which necessitates strict controls on its storage and administration.

Q: Is it true that Kalipsol can affect memory?

Studies and official product information indicate that the medication may be associated with impaired memory. Short-term cognitive deficits have been reported in connection with its use, particularly in cases of chronic abuse or repeated exposure.

Q: How does Kalipsol interact with antidepressants?

Official regulatory information specifies that Ketamine may interact with certain types of antidepressants. For instance, combining it with Monoamine Oxidase Inhibitors ( MAOIs) may potentially lead to an unsafe rise in blood pressure, which requires careful clinical consideration.

Q: Does Kalipsol affect the ability to drive a car?

Official prescribing documents include a specific warning regarding post-administration activity, noting that activities requiring full alertness, such as driving or operating hazardous machinery, are generally restricted for a period of 24 hours or more.

Q: What happens in case of accidental overdose of Kalipsol?

Overdose can result in severe central nervous system effects, including unconsciousness, dangerously slowed breathing, and potentially coma. Official protocols state that treatment for overdose is supportive and symptomatic, focusing on managing vital functions, as there is no specific antidote available.

Q: Is it true that Kalipsol is used in veterinary medicine?

Yes, the active substance Ketamine is documented in regulatory sources to be approved for use in veterinary medicine. It is used as an anesthetic agent and for restraint in certain non-human species, such as cats and subhuman primates.

Q: Are cases of Kalipsol interaction with food products described in official sources?

Official regulatory information describes a potential for increased blood levels and a higher risk of side effects when the medication is combined with grapefruit or grapefruit juice.

Q: Does taking Kalipsol affect body weight?

While significant change in body weight is not listed as a common reaction, official side effect listings do include loss of appetite (anorexia) as a possible adverse effect.

Storage and Disposal Requirements for Калипсол (Ketamine)

Storage Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	The product must be protected from light and kept in its original container.
Security	Store securely, complying with all controlled substance regulations, and keep out of the sight and reach of children.
Stability	If the injection is diluted or opened, the solution should typically be used immediately or discarded according to the labeled in-use stability period.
Disposal	Disposal of all unused or expired medicine inventory must follow authorized procedures for controlled substances to render the product non-retrievable.